Sarepta Therapeutics Announces FDA Approval of AMONDYS 45? (casimersen)

1596553509280

2021-03-03

-- AMONDYS 45 is Sarepta?s third RNA exon-skipping treatment for DMD approved in the U.S. --

-- Commercial distribution of AMONDYS 45 in the U.S. will commence immediately --

-- Information for patients and clinicians is available at www.SareptAssist.com --